Introduction：Basic information about CAS 31721-17-2|quinupramine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | quinupramine |
|---|
| CAS Number | 31721-17-2 | Molecular Weight | 304.43 |
|---|
| Density | 1.19g/cm3 | Boiling Point | 445.2ºC at 760mmHg |
|---|
| Molecular Formula | C21H24N2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 201.7ºC |
|---|
Names
| Name | 11-(1-azabicyclo[2.2.2]octan-3-yl)-5,6-dihydrobenzo[b][1]benzazepine |
|---|
| Synonym | More Synonyms |
|---|
quinupramine BiologicalActivity
| Description | Quinupramine is an orally active antidepressant. Quinupramine can penetrate into the CNS and affect some of the processes of neurotransmission. The antidepressant activity of quinupramine is associated with the central serotonin system, but not with the β-adrenergic system[1][2]. |
|---|
| Related Catalog | Research Areas >>Neurological Disease |
|---|
| In Vivo | Quinupramine (10 mg/kg, PO, twice daily for 10 days) causes a down-regulation of serotonin S2 receptors in the frontal cortex of the rat[2]. Quinupramine-EVA matrix containing a permeation enhancer can be a good transdermal delivery system for providing sustained plasma concentrations[3]. Animal Model: Sprague-Dawley rats (Male, 220-270 g) Dosage: 10 mg/kg Administration: PO, twice daily for 10 days Result: Caused a down-requlation of serotonin S2 receptors in the frontal cortex of the rat, did not alter the binding populations of Q-adrenergic, muscarinic cholinergic and a2-adrenergic receptors in the rat brain. |
|---|
| References | [1]. [1] Sakamoto H, et al. Effects of quinupramine on the central monoamine uptake systems and involvement of pharmacokinetics in its pharmacological activities. Jpn J Pharmacol. 1987;45(2):169-175. [2]. [2] Sakamoto H, et al. Down-regulation of central serotonin S2 receptors after repeated treatment with quinupramine in rats. Jpn J Pharmacol. 1987;43(4):369-377. [3]. [3] Shin SC, et al. Development and biopharmaceutical evaluation of quinupramine-EVA matrix containing penetration enhancer for the enhanced transdermal absorption in rats. Pharm Dev Technol. 2007;12(5):429-436. |
|---|
Chemical & Physical Properties
| Density | 1.19g/cm3 |
|---|
| Boiling Point | 445.2ºC at 760mmHg |
|---|
| Molecular Formula | C21H24N2 |
|---|
| Molecular Weight | 304.43 |
|---|
| Flash Point | 201.7ºC |
|---|
| Exact Mass | 304.19400 |
|---|
| PSA | 6.48000 |
|---|
| LogP | 4.02040 |
|---|
| Index of Refraction | 1.667 |
|---|
| InChIKey | JCBQCKFFSPGEDY-UHFFFAOYSA-N |
|---|
| SMILES | c1ccc2c(c1)CCc1ccccc1N2C1CN2CCC1CC2 |
|---|
Safety Information
| RIDADR | UN 3249 |
|---|
| Packaging Group | III |
|---|
| Hazard Class | 6.1(b) |
|---|
| HS Code | 2933990090 |
|---|
Customs
| HS Code | 2933990090 |
|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| Quinupraminum |
| Kinupril |
| Kevopril |
| Quinupramina |
| Quinupramine |
